Strategy & Funds - Claris Ventures

Strategy

Claris Ventures is the first VC firm in Italy with focus on biopharma projects ready to start clinical studies in 12-24 months. Our team provides resources, capabilities and connections to complete preclinical studies and run first in human trials. We are particularly interested in oncology, immunology, rare diseases and other therapeutic areas with limited treatment opportunities.

Claris Ventures allows scientific founders to focus on science and development, while supporting project management, finance and strategic development.

Proof of Concept

Pre-clinical

Claris Ventures
investment sweet-spot

Exit

Clinical

Funds

Claris Ventures manages specialized venture capital funds focused on early-stage biotech company creation and development. Our funds invest in innovative therapeutic programs originating from top academic research and entrepreneurial teams, with the goal of building clinically meaningful and globally relevant biotech companies.

Claris Biotech I

Claris Biotech I was launched in September 2020 and raised a total of €85 million.
The fund focuses on seed and Series A investments in early-stage biotech companies, supporting company creation, scientific validation, and the transition from discovery to clinical development.

Claris Biotech I has built a diversified portfolio across multiple therapeutic areas, working hands-on with founders and management teams to shape strategy, build organizations, and prepare companies for subsequent financing rounds and strategic partnerships.

Claris Biotech II

Building on the experience and track record of the first fund, Claris Biotech II was launched in April 2025 with a target size of €100 million.

The fund continues Claris Ventures’ focus on early-stage biotech investments, with an emphasis on first-in-class and best-in-class therapeutics. Claris Biotech II is currently in fundraising and aims to further strengthen Claris’ role as a leading biotech venture capital platform in Italy, while expanding its international reach.